Table 2 |
|||||||
|
Univariable meta-regression of bupropion studies. |
|||||||
|
Covariates |
Point estimate |
Lower 95% limit |
Upper 95% limit |
OR |
Lower 95% limit |
Upper 95% limit |
p-value |
|
|
|||||||
|
Placebo |
2.00 |
-0.14 |
4.15 |
7.38 |
0.86 |
63.4 |
0.07 |
|
Sequence generation |
-0.46 |
-0.84 |
-0.08 |
0.63 |
0.43 |
0.92 |
0.01 |
|
Allocation concealment |
-0.20 |
-0.55 |
0.14 |
0.81 |
0.57 |
1.15 |
0.25 |
|
CO |
0.76 |
0.06 |
1.46 |
2.13 |
1.06 |
4.30 |
0.03 |
|
Cotinine |
-0.76 |
-1.46 |
-0.06 |
0.46 |
0.23 |
0.94 |
0.03 |
|
Planned to quit |
0.13 |
-0.22 |
0.48 |
1.13 |
0.80 |
1.61 |
0.46 |
|
|
|||||||
|
Legend. The point estimate and 95% CIs estimate the unit change in the effect size, whenever the predicted covariate is present. The OR for the point estimates and 95% CI denote the likelihood of covariate affecting the trial effect size. |
|||||||
|
Wu et al. BMC Public Health 2006 6:300 doi:10.1186/1471-2458-6-300 |
|||||||